EPIS® Právní systém | Plné znění

XXXXXXXX XXXXXX X XXXXXXXXX PRAVOMOCI (EU) 2020/1182

xx dne 19. xxxxxx 2020,

kterým se xxx účely xxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxxx xxxxxxx xxxx část 3 xxxxxxx VI xxxxxxxx Xxxxxxxxxx parlamentu x Rady (XX) x. 1272/2008 o xxxxxxxxxxx, xxxxxxxxxx x xxxxxx látek x xxxxx

(Xxxx x významem xxx XXX)

XXXXXXXX KOMISE,

s xxxxxxx xx Xxxxxxx x xxxxxxxxx Evropské xxxx,

x ohledem na xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady (ES) x. 1272/2008 ze xxx 16. xxxxxxxx 2008 x xxxxxxxxxxx, xxxxxxxxxx x balení xxxxx x směsí, x změně x xxxxxxx směrnic 67/548/XXX x 1999/45/ES a x xxxxx xxxxxxxx (XX) č. 1907/2006 (1), x xxxxxxx na xx. 37 xxxx. 5 uvedeného nařízení,

vzhledem x xxxxx xxxxxxx:

(1)	Xxxxxxx 3 x xxxxx 3 xxxxxxx XX xxxxxxxx (XX) č. 1272/2008 obsahuje seznam xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxxxxx xxxxx xx xxxxxxx xxxxxxxx xxxxxxxxxxx x xxxxxxx 2 xx 5 xxxxxxx X xxxxxxxxx xxxxxxxx.

(2)

Xxxxxxxx agentuře xxx xxxxxxxx látky („xxxxxxxx“) xxxx x souladu x xxxxxxx 37 xxxxxxxx (ES) x. 1272/2008 xxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxx x xxxxxxxxxxx nebo zrušení xxxxxxxxxxxxxxx klasifikací a xxxxxxxx xxxxxxxxx xxxxxx xxxxx. Xx xxxxxxx xxxxxxxxxx&xxxx;(2) x xxxxx xxxxxxx, xxxxx xxxxx Xxxxx xxx xxxxxxxxxx xxxxx („RAC“) xxxxxxxx, xxxxx x xxxxxxxxxx xxxxxxxxxxxx stran, xx xxxxxx xxxxxx, xxxxxxxxxxxx xx xxxxxx xxxxxxxxxxxxx xxxxxxxxxxx a xxxxxxxx xxxxxxxxx látek. Uvedená xxxxxxxxxx výboru RAC xxxx:

—	xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxx xxxxxxx... %[X ≤ 70 %],

—	xxxxxxxxxx ze xxx 9. xxxxxx 2018 xxxxxxx xxxxxx x xxxxxxx křemíku (x xxxxxxx &xx; 3 μx,xxxxx > 5 μx a xxxxxx xxxxx ≥ 3:1),

—	xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxx(xxxxx)xxxxxx,

—	xxxxxxxxxx ze xxx 8. xxxxxx 2018 ohledně xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxxx, 6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 8. června 2018 xxxxxxx xxxxxxxx-xxxxxxxxx,

—	xxxxxxxxxx xx xxx 8. xxxxxx 2018 ohledně xxxxxxxxxxx xxxx,

—	xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx xxx (X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)-xxxx, xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxxx, [Xx-XXX],

—	xxxxxxxxxx xx xxx 14. září 2018 xxxxxxx xxxxxxxxxx-xxxxxxxxx, [1] xxxxxxxx, dioktyl-, xxx(xxxx xxxxxxx) xxxxxxxx [2],

—	xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx xxxxxxx[xxx,x]xxxxxxxx, xxxxxxx[x,x]xxxxxx,

—	xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx (XXX), (1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorbenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyklopentanolu,

—	stanovisko xx xxx 8. xxxxxx 2018 xxxxxxx xxx(2-(2-xxxxxxxxxxxxx)xxxxx)xxxxxx, xxxxxxxxxx,

—	xxxxxxxxxx ze xxx 8. xxxxxx 2018 ohledně paklobutrazolu (XXX), (2RS,3RS)-1-(4-chlorofenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-olu,

—	stanovisko xx xxx 8. xxxxxx 2018 xxxxxxx 2,2-bis(brommethyl)propan-1,3-diolu,

—	stanovisko xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxx, (2E)-3,7-dimethylokta-2,6-dien-1-olu,

—	stanovisko xx xxx 28. ledna 2019 xxxxxxx 2-(4-xxxx-xxxxxxxxxxx)xxxxxxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně XXXX-xxxxxxxxxx (ISO), X-xxxxx (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxxx, S-ethyl 4-chlor-o-tolyloxythioacetátu,

—	stanovisko xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx,

—	xxxxxxxxxx ze dne 14. xxxx 2018 xxxxxxx 4-{[(6-xxxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xxx, flupyradifuronu,

—	stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxx-xxxxxxx (ISO), methyl 4- [(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxxx,

—	xxxxxxxxxx ze xxx 9. března 2018 xxxxxxx X-(+)-xxxxxx xxxxxxxx, (2X)-2-xxxxxxxxxxxxxxxx xxxxxxxx,

—	xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx 2-xxxxxxxxxxxx-xxxxxxxx,

—	xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx xxxxxxxxxx xxxxxxxx …%,

—	xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx, [xxxxxxxxxxx xxxxxxxx x natria-N-(hydroxymethyl)glycinátu],

—	stanovisko xx dne 30. xxxxxxxxx 2018 xxxxxxx (xxxxx-XXX-xxxxx)xxxxxxxxxxx xxxxxxxxxx, xxxxxxxxxx(xxxxxxx)xxxxxx-1-xxxxx, xxxxxxxx soli, [X-XXX],

—	xxxxxxxxxx xx dne 14. xxxx 2018 ohledně xxxxxxxxxxx-xxxxxxxxxxx, X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxxx, xxxxxxxxxxx-xxxxx-xxxxxxx [XXX],

—	xxxxxxxxxx xx dne 9. xxxxxx 2018 xxxxxxx (2RS)-2-[4-(4-chlorfenoxy)-2(trifluoromethyl)fenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-olu, xxxxxxxxxxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxx (ISO), 1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxxx,

—	xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxx-xxxxx, (X-4)-xxx[1-(xxxxxxx-xxxxx-X)xxxxxxx-2(1X)-xxxxxxx-xxxxx-X]xxxxx,

—	xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně 3-xxxxx-4-(xxxxxxxxxxx)-1-[3-xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xxx, xxxxxxxxxxxxxxx (ISO),

—	stanovisko ze xxx 30. xxxxxxxxx 2018 xxxxxxx 4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXXXX],

—	xxxxxxxxxx xx xxx 8. června 2018 xxxxxxx 2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xxx, [XXXX],

—	xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxxx, xxxxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx X-(xxxxxxxxxxxxx)xxxxxxxxxx, xxxxxxxxxxxxxxxxxx, [XXX],

—	xxxxxxxxxx ze xxx 15. října 2018 xxxxxxx 5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxxx, 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxxx, penflufenu,

—	stanovisko ze xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxx (XXX), isopropyl [(2S)-3-methyl-1-{[1-(4-methylfenyl)ethyl]amino}-1-oxobutan-2-yl]karbamátu,

—	stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxx (XXX), X-xxxxx-4,5-xxxxxxxx-2(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxx, xxxxxxx [olej xxxxxxxx xx xxxxxxx xx semen xxxxxxxx Xxxxxxxxxxx xxxxxx xxx xxxxxxxx, xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxx xxxxxxxxx],

—	xxxxxxxxxx xx xxx 8. xxxxxx 2018 ohledně xxxxxxxx xxxxxxx …%[C> 70 %],

—	xxxxxxxxxx x 9. xxxxxx 2018 ohledně xxxxxxxxxxxxxxxxxxxxxxxxxxxx, [X4],

—	xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně xxxxxxxxx-xxxxxxx (XXX), O-[2-(diethylamin)-6-methylpyrimidin-4-yl]-O,O-dimethyl-fosforthioátu,

—	stanovisko ze 30. xxxxxxxxx 2018 xxxxxxx xxxxxxx,

—	xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxxx,

—	xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx 2-xxxxxxxxxx-10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxx-xxxxxxxxx, [DOTE],

—	stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxx,

—	xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx 2-xxxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx,

—	xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx x-xxx(2,3-xxxxxxxxxxxx)xxxxxxx, xxxxxxxxxx-xxxxxxxxxx-xxxxxx,

—	xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx (XXX), xxxxxx 2-[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)-X-xxxxxxxxxxxxxxxxxxxxxxxx]xxxxxxxx,

—	xxxxxxxxxx ze xxx 8. června 2018 ohledně xxxxxxxxxxxxx (XXX), methyl (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (ISO), (XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx-xxxxxxxxxxxxxxx,

—	xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 xxxxxxx 2,4-xxxxxxxxxxxxx,

—	xxxxxxxxxx ze dne 14. xxxx 2018 xxxxxxx mesotrionu (ISO), 2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx okthilinonu (XXX), 2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXX],

—	xxxxxxxxxx ze xxx 14. xxxx 2018 ohledně xxxxxxxxxx (XXX), 3-xxxxxxx-5-xxxxxxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxx (XXX), (X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxx-xxxxx)-1,2,4-xxxxxxx-3(2X)-xxx,

—	xxxxxxxxxx ze xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), reakční xxxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxxx, [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxxxx-xxxxxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 14. září 2018 xxxxxxx-xxxxx, xxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxx(α,α-xxxxxxxxxxxxxx)-xxxxxxxx,

—	xxxxxxxxxx ze xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxx,

—	xxxxxxxxxx ze xxx 30. listopadu 2018 xxxxxxx xxxxx 2-(1-(diethylaminohydroxyfenyl) xxxxxxxxx)xxxxxxxx, xxxxx 2-[4-(diethylamin)-2-hydroxybenzoyl]benzoátu.

(3)

Pokud xxx x xxxxx xxxxx (xxxxx XXX 7439–92–1 a xxxxxxxx xxxxx 082–013–00–1 (xxxxx x xxxxxx; [xxxxxx xxxxxx < 1 xx];) x 082–014–00–7 (xxxxxxxx xxxxx; [xxxxxx xxxxxx ≥ 1 xx];)), RAC xx xxxx xxxxxxxxxx ze xxx 30. listopadu 2018 xxxxxx použít xxxxxxx environmentální xxxxxxxxxxx xx celistvou i xxxxxxxxx xxxxx. Avšak xxxxxxxx k xxxxx xxxxxxxxx rozpouštění xxxxxxxx xxxxx, xxxxxx xxxxxxxxx xxxxx, xx xxxxxxxxxx xxxxxxx xxxxxx prášku x vzhledem x xxxxx environmentální xxxxxxxxxxx x celistvých x xxxxxxxxxx xxxxx xxxxxx xxxx x xxxxxxxxxxxx xxxxxxxxx v xxxxxxx XX xxxx XXX xxxxxxx xxxxx xxxxxxxxx xxxx, zda xx xxx xx xxxxxxxxx x práškovou xxxxx xxxxx xxxxxxx xxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx. Kromě xxxx byly xxxxxxxxxx xxxx xxxxxxx xxxxxxxx, x nichž xxxxxxx, xx environmentální xxxxxxxxxxx xxx celistvou formu, xxx xx xxxxxxxxxx xxxxxxxxxx xxxxxx RAC, xxxxxx xxx xxxxxx. Xxxxxxxxxxxxxxx xxxxxxxxxxx pro xxxxxxxxx xxxxx xxxxx xxxxxx xxxxxxxx do xxxxxxx VI xxxxxxxx (XX) č. 1272/2008, xxxxx XXX xxxxxx xxx možnost předložit xxxxxxxxxx xxxxxxxxxx.

(4)

Xxxxx xxx x látku 2-xxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxx, (číslo CAS 111-76-2), xxx třídu xxxxxxxxxxxxx „xxxxxx xxxxxxxx (xxxxxxxxx)“ byly xxxxxxxxxx xxxx vědecké xxxxxxxx, xx xxxxxxx vyplývá, xx xxxxxxxxxxx xxx xxxx třídu nebezpečnosti xxxxxxxxxxxx ve xxxxxxxxxx xxxxxx RAC, jež xx zakládá na xxxxxxxx xxxxxxx, xxxxxx xxx vhodná. Xxxx xxxxx xxxxxxxxxxxxx xx xxxxx xxxxxx xxx x xxxxxxx VI xxxxxxxx (XX) x. 1272/2008 xxxxxxx, dokud XXX nebude mít xxxxxxx xxxxxxxxx k xxxxx novým xxxxxxxxxx xxxxxxxxxx xxxxxxxxxx; xxxxxxx xxxxxxx xxxxx nebezpečnosti, x xxxxxxx pojednává xxxxxxxxxx výboru XXX, xx xxxxxxxx xxx xxxx.

(5)	Xxxxxxxx (ES) č. 1272/2008 xx proto xxxx xxx xxxxxxxxxxxxx xxxxxxxx xxxxxxx.

(6)

Xxxxxxxxxx xxxxxx xxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx xx xxxxxx xxx, x xxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx požadavků, xxxxxxxxxx xxxxx, xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxx na xx, xxx xxxxxxxxxxxx xxxxxxxxxx x xxxxxx látek x xxxxx xxxxx xxxx xxxxxxxxxxx xxxxxxxxxxxx x xxxxxxx xxxxxxxxx xxxxxx. Xxxx xxxx xx xxxxxx nezbytná x xxxx, aby xxxxxxxxxx měli xxxxxxxx xxxx přijmout opatření xxxxx k xxxxxxxxx xxxxxxxx dodržování dalších xxxxxxxx xxxxxxxxx, xxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxx xxxxx xxxxxx xxxxxxxx. Xxxx xxxxxxxxx mohou xxxxxxxxx xxxxxxxxx xxxxxxxxx x xx. 22 odst. 1 xxxx. f) xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 1907/2006 (3) xxxx xxxxxxxxx stanovené v xxxxxx 50 nařízení Xxxxxxxxxx xxxxxxxxxx a Xxxx (XX) č. 528/2012&xxxx;(4).

(7)	Xxxxxxxxxxx xx však xxxx xxx umožněno, xxx xxxxx xxxx xxxxxxxxxx týkající xx xxxxxxxxxxx, xxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx xxxx xxxxxxxxxxxxx xxxxxx xxxxxxxx. Xx xx x xxxxxxx x přístupem podle xx. 61 xxxx. 2 xxxxxxxx (XX) x. 1272/2008,

PŘIJALA XXXX XXXXXXXX:

Článek 1

Xxxxx xxxxxxxx (XX) č. 1272/2008

Tabulka 3 x xxxxx 3 xxxxxxx XX xxxxxxxx (XX) č. 1272/2008 xx xxxx x xxxxxxx x xxxxxxxx xxxxxx xxxxxxxx.

Xxxxxx 2

Xxxxx v xxxxxxxx x xxxxxxxxxxxx

Xxxx xxxxxxxx xxxxxxxx v xxxxxxxx xxxxxxxx xxxx xx vyhlášení x Xxxxxxx xxxxxxxx Xxxxxxxx xxxx.

Xxxxxxx se xxx xxx 1. března 2022.

Xxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xxxxxx xxxxx xxx látky x xxxxx xxxxxxxxxxxxx, xxxxxxxxxx x baleny x xxxxxxx s xxxxxxxxx (XX) č. 1272/2008 xx znění xxxxxx xxxxxxxx xxxxx xxxxx xxxx 1. xxxxxx 2022.

Xxxx xxxxxxxx xx xxxxxxx x xxxxx xxxxxxx x přímo xxxxxxxxxx xx xxxxx xxxxxxxxx xxxxxxx.

X Bruselu xxx 19. května 2020.

Xx Komisi

Ursula VON XXX LEYEN

předsedkyně

(1) manaÚř. xxxx. X 353, 31.12.2008, x. 1.

(2)&xxxx;&xxxx;Xxxxxxxxxx xxxx xxxxxxxx xx xxxx xxxxxxxxxxx stránce: https://echa.europa.eu/registry-of-clh-intentions-until-outcome/-/dislist/name/-/ecNumber/-/casNumber/-/dte_receiptFrom/-/dte_receiptTo/-/prc_public_status/Opinion+Adopted/dte_withdrawnFrom/-/dte_withdrawnTo/-/sbm_expected_submissionFrom/-/sbm_expected_submissionTo/-/dte_finalise_deadlineFrom/-/dte_finalise_deadlineTo/-/haz_addional_hazard/-/lec_submitter/-/dte_assessmentFrom/-/dte_assessmentTo/-/prc_regulatory_programme/-/

(3) Nařízení Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) č. 1907/2006 xx xxx 18. prosince 2006

x xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx x omezování xxxxxxxxxx xxxxx, x xxxxxxx Xxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxx, x xxxxx směrnice 1999/45/XX x x xxxxxxx xxxxxxxx Rady (XXX) x. 793/93, xxxxxxxx Xxxxxx (ES) x. 1488/94, xxxxxxxx Xxxx 76/769/XXX x směrnic Xxxxxx 91/155/EHS, 93/67/XXX, 93/105/XX a 2000/21/XX (Xx. xxxx. X 396, 30.12.2006, s. 1).

(4)&xxxx;&xxxx;Xxxxxxxx Evropského parlamentu x Rady (EU) x. 528/2012 xx xxx 22. xxxxxx 2012

x xxxxxxxx xxxxxxxxxx xxxxxxxxx na xxx x xxxxxx xxxxxxxxx

(Xx. xxxx. X 167, 27.6.2012, x. 1).

PŘÍLOHA

V příloze XX xxxxxxxx (XX) x. 1272/2008 xx xxxxxxx 3 x části 3 mění takto:

Vkládají xx xxxx xxxxxxx:

Xxxxxxxx xxxxx	Xxxxxxxx xxxxx	Xxxxx XX	Xxxxx XXX	Xxxxxxxxxxx		Xxxxxxxx			Xxxxxxxxxx xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx a XXX	Xxxxxxxx
Xxxxxxxx xxxxx	Xxxxxxxx xxxxx	Xxxxx XX	Xxxxx XXX	Xxxx tříd x xxxxxxxxx nebezpečnosti	Kódy xxxxxxxxxxxx xxx x xxxxxxxxxxxxx	Xxxx xxxxxxxxxxx xxxxxxx a xxxxxxxxxx xxxx	Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx	Xxxx xxxxx. standardních xxx x xxxxxxxxxxxxx	Xxxxxxxxxx xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx a XXX	Xxxxxxxx
„007-030-00-3	xxxxxxxx xxxxxxx …% [C ≤ 70 %]	231-714-2	7697-37-2.	Xx. Xxx. 3 Xxxxx Tox. 3 Skin Xxxx. 1 A	H272 H331 H314	GHS03 GHS06 GHS05 Dgr	H272 H331 H314	EUH071	Ox. Xxx. 3; X272: X ≥ 65 % xxxxxxxxx: ATE = 2,65 xx/x (xxxx) Xxxx Xxxx. 1 X; X314: X ≥ 20 % Xxxx Xxxx. 1X; H314: 5 % ≤ X &xx; 20 %	B“
„014-048-00-5	vlákna x karbidu křemíku (x xxxxxxx &xx; 3 μm, xxxxx &xx; 5 μm x x xxxxxxx xxxxx ≥ 3:1)	206-991-8	409-21-2 308076-74-6	Xxxx. 1X	X350x	XXX08 Xxx	X350x“
„014-049-00-0	xxxxxxxxxxxxxxxxxxxx; xxxxxxxxxx(xxxxx)xxxxx	220-449-8	2768-02-7	Xxxx Sens. 1X	X317	XXX07 Xxx	X317“
„014-050-00-6	xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxx; 6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxx	213-934-0	1067-53-4	Xxxx. 1X	X360XX	XXX08 Xxx	X360XX“
„016-098-00-3	xxxxxxxx-xxxxxxxx	210-871-0	624-92-0	Xxxx. Xxx. 2 Xxxxx Tox. 3 Xxxxx Xxx. 3 STOT XX 3 XXXX XX 1 Xxx Xxxxx. 2 Skin Xxxx. 1 Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1	X225 X331 X301 X336 X370 (xxxxx xxxxxxx cesty, vdechnutí) H319 H317 H400 H410	GHS02 GHS06 GHS08 GHS09 Dgr	H225 H331 H301 H336 H370 (xxxxx xxxxxxx xxxxx, xxxxxxxxx) X319 X317 X410		xxxxxxxxx: ATE = 5 xx/x (páry) orální: XXX = 190 xx/xx XX X = 1 X = 10“
„029-024-00-X	xxxxxxxxxxx xxx; [xxxxx částic: xx 0,9 xx a xx 6,0 xx; xxxxx částic: xx 0,494 xx 0,949 xx]	231-159-6	7440-50-8	Xxxxxxx Xxxxxxx 2	X411	XXX09	X411“
„029-025-00-5	xxx(X-xxxxxxx-X-xxxxxxxxxxxxxxxxxxxxxxxx-X,X’)xxx; xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxx; [Xx-XXX]	239-703-4	312600-89-8 15627-09-5	Xxxx. Xxx. 1 Xxxxx Tox. 4 XXXX XX 2 Xxx Xxx. 1 Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1	X228 X302 X373 (xxxxx) X318 X400 X410	XXX02 XXX07 XXX08 XXX05 XXX09 Xxx	X228 X302 X373 (játra) H318 H410		orální: XXX = 360 xx/xx XX X = 1 X = 1“
„050-031-00-9	xxxxxxxxxx-xxxxxxxx; [1] xxxxxxx, xxxxxxx-, xxx(xxxx acyloxy) xxxxxxxx [2]	222-883-3 [1] 293-901-5 [2]	3648-18-8 [1] 91648-39-4 [2]	Xxxx. 1X XXXX XX 1	X360X X372 (imunitní xxxxxx)	XXX08 Xxx	X360X X372 (xxxxxxxx xxxxxx)“
„601-092-00-0	xxxxxxx[xxx,x]xxxxxxx; xxxxxxx[x,x]xxxxx	205-886-4	191-30-0	Xxxx. 1X Xxxx. 2	X350 X341	XXX08 Xxx	X350 X341		Xxxx. 1X; X350: X ≥ 0,001 %“
„603-237-00-3	xxxxxxxxx (ISO); (1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorbenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyklopentanol	–	125225-28-7 115850-69-6 115937-89-8	Repr. 1X Xxxxx Xxx. 4 XXXX XX 2 Aquatic Xxxxxxx 1	X360X X302 X373 (xxx, kůže, xxxxx) X410	XXX08 XXX07 XXX09 Xxx	X360X X302 X373 (oči, xxxx, xxxxx) X410		xxxxxx: XXX = 500 mg/kg TH M = 100“
„603-238-00-9	xxx(2-(2-xxxxxxxxxxxxx)xxxxx)-xxxxx; xxxxxxxxx	205-594-7	143-24-8	Xxxx. 1X	X360XX	XXX08 Xxx	X360XX“
„603-239-00-4	xxxxxxxxxxxxx (XXX); (2XX,3XX)-1-(4-xxxxxxxxxx)-4,4-xxxxxxxx-2-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-3-xx	–	76738-62-0	Xxxx. 2 Xxxxx Xxx. 4 Acute Xxx. 4 Xxx Irrit. 2 Xxxxxxx Xxxxx 1 Aquatic Chronic 1	X361x X332 X302 X319 X400 X410	XXX08 XXX07 XXX09 Xxx	X361x X332 X302 X319 X410		xxxxxxxxx: XXX = 3,13 xx/x (xxxxx xxxx xxxx) xxxxxx: ATE = 490 xx/xx XX X = 10 M = 10“
„603-240-00-X	2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxx	221-967-7	3296-90-0	Xxxx. 1X Xxxx. 1X	X350 X340	XXX08 Xxx	X350 X340“
„603-241-00-5	xxxxxxxx; (2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xx	203-377-1	106-24-1	Xxxx Sens. 1	H317	GHS07 Wng	H317“
„605-041-00-3	2-(4-terc-butylbenzyl)propanal	201-289-8	80-54-6	Repr. 1X	X360Xx	XXX08 Xxx	X360Xx“
„607-738-00-8	XXXX-xxxxxxxxx (ISO); S-ethyl (4-chlor-2-methylfenoxy)ethanethioát; X-xxxxx 4-chlor-o-tolyloxythioacetát	246-831-4	25319-90-8	Acute Xxx. 4 XXXX XX. 2 Xxxxxxx Xxxxx 1 Aquatic Xxxxxxx 1	H302 H373 (xxxxx) X400 X410	XXX07 XXX08 XXX09 Xxx	X302 X373 (xxxxx) X410		xxxxxx: XXX = 450 mg/kg TH M = 10 M = 10“
„607-740-00-9	xxxxxxxxxx-xxxxxx	248-523-5	27554-26-3	Xxxx. 1X	X360XX	XXX08 Xxx	X360XX“
„607-741-00-4	4-{[(6-xxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xx; xxxxxxxxxxxxxx	–	951659-40-8	Xxxxx Xxx. 4 STOT XX 2 Xxxxxxx Xxxxx 1 Aquatic Xxxxxxx 1	H302 H373 (svalovina) H400 H410	GHS07 GHS08 GHS09 Wng	H302 H373 (xxxxxxxxx) X410		xxxxxx: XXX = 500 xx/xx XX X = 10 M = 10“
„607-742-00-X	xxxxxxxxxxxxx-xxxxxx (XXX); xxxxxx-4-[(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxx	–	317815-83-1	Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1	H400 H410	GHS09 Wng	H410		M = 1000 X = 1000“
„607-743-00-5	X-(+)-xxxxxx kyselina; (2 S)-2-hydroxypropanová xxxxxxxx	201-196-2	79-33-4	Xxxx Corr. 1C Eye Xxx. 1	H314 H318	GHS05 Dgr	H314	EUH071“
„607-744-00-0	2-methoxyethylakrylát	221-499-3	3121-61-7	Flam. Xxx. 3 Xxxx. 2 Xxxx. 1X Xxxxx Xxx. 3 Xxxxx Xxx. 4 Xxxx Xxxx. 1X Xxx Xxx. 1 Xxxx Xxxx. 1	X226 X341 X360XX X331 X302 X314 X318 X317	XXX02 XXX05 XXX06 XXX08 Xxx	X226 X341 X360XX X331 X302 X314 X317	XXX071	xxxxxxxxx: XXX = 2,7 xx/x (xxxx) xxxxxx: XXX = 404 xx/xx TH“
„607-745-00-6	glyoxylová kyselina …%	206-058-5	298-12-4	Xxx Xxx. 1 Xxxx Xxxx. 1B	H318 H317	GHS05 GHS07 Dgr	H318 H317			B“
„607-746-00-1	natrium-N-(hydroxymethyl)glycinát; [formaldehyd xxxxxxxx x xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx]	274-357-8	70161-44-3	Xxxx. 1B Muta. 2 Xxxxx Xxx. 4 Xxxxx Xxx. 4 STOT XX 3 Xxxx Xxxxx. 2 Eye Xxxxx. 2 Skin Xxxx. 1	X350 X341 X332 X302 X335 X315 X319 X317	XXX08 XXX07 Xxx	X350 X341 X332 X302 X335 X315 X319 X317		xxxxxxxxx: XXX = 3 xx/x (xxxxx xxxx xxxx) xxxxxx: XXX = 1 100 mg/kg XX	8 9“
„611-181-00-6	(xxxxx-XXX-xxxxx)xxxxxxxxxx xxxxxxxx; xxxxxxxxxxxxxxxxxxxxxxx-1-xxxx, draselná xxx; [X-XXX]	–	66603-10-9	Xxxx. Sol. 1 Xxxxx Xxx. 3 STOT RE 2 Xxxx Irrit. 2 Xxx Xxx. 1 Aquatic Xxxxxxx 2	X228 X301 X373 (játra) H315 H318 H411	GHS02 GHS06 GHS08 GHS05 GHS09 Dgr	H228 H301 H373 (xxxxx) X315 X318 X411		xxxxxx: XXX = 136 xx/xx XX“
„612-294-00-3	xxxxxxxxxxxxxxxxxxxxx; X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxx; xxxxxxxxxxx-xxxxx-xxxxxx; [XXX]	221-106-5	3006-10-8	Xxxx Xxxx. 1 Xxx Xxx. 1 Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1	X314 X318 X400 X410	XXX05 XXX09 Xxx	X314 X410	XXX071	X = 100 X = 1&xxxx;000 “
„613-331-00-6	(2XX)-2-[4-(4-xxxxxxxxxxx)-2-(xxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xx; xxxxxxxxxxxxxxxxxx	–	1417782-03-6	Xxxx Xxxx. 1 Aquatic Acute 1 Xxxxxxx Xxxxxxx 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410		M = 1 X = 1“
„613-332-00-1	xxxxxxxxxxxxxxx (XXX); 1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxx	–	1003318-67-9	Xxxxxxx Xxxxxxx 1	X410	XXX09 Xxx	X410		X = 1“
„613-333-00-7	pyrithion-zinek; (X-4)-xxx[1-(xxxxxxx-.xxxxx.X)xxxxxxx-2(1X)-xxxxxxxx-.xxxxx.X]xxxxx	236-671-3	13463-41-7	Xxxx. 1X Xxxxx Xxx. 2 Xxxxx Xxx. 3 XXXX XX 1 Xxx Dam. 1 Xxxxxxx Acute 1 Xxxxxxx Xxxxxxx 1	X360X X330 X301 X372 X318 X400 X410	XXX08 XXX06 XXX05 XXX09 Xxx	X360X X330 X301 X372 X318 X410		xxxxxxxxx: ATE = 0,14 mg/l (xxxxx xxxx xxxx) xxxxxx: XXX = 221 xx/xx TH M = 1&xxxx;000 X = 10“
„613-334-00-2	flurochloridon (XXX); 3-xxxxx-4-(xxxxxxxxxxx)-1-[3-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xx	262-661-3	61213-25-0	Xxxx. 1X Xxxxx Xxx. 4 Xxxx Xxxx. 1 Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1	X360XX X302 X317 X400 X410	XXX08 XXX07 XXX09 Xxx	X360XX X302 X317 X410		xxxxxx: ATE = 500 xx/xx XX X = 100 M = 100“
„613-335-00-8	4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xx; [DCOIT]	264-843-8	64359-81-5	Acute Tox. 2 Xxxxx Tox. 4 Xxxx Xxxx. 1 Xxx Dam. 1 Xxxx Sens. 1 X Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1	X330 X302 X314 X318 X317 X400 X410	XXX06 XXX05 XXX09 Xxx	X330 X302 X314 X317 X410	XXX071	xxxxxxxxx: XXX = 0,16 xx/x (xxxxx xxxx xxxx) xxxxxx: XXX = 567 xx/xx XX Xxxx Xxxxx. 2; X315: 0,025 % ≤ X &xx; 5 % Eye Xxxxx. 2; X319: 0,025 % ≤ X &xx; 3 % Xxxx Xxxx. 1 X; X317: X ≥ 0,0015 % X = 100 X = 100“
„613-336-00-3	2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx; [XXXX]	–	2527-66-4	Xxxxx Xxx. 4 Acute Xxx. 3 Xxxx Xxxx. 1X Xxx Xxx. 1 Xxxx Xxxx. 1 X Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 2	X312 X301 X314 X318 X317 X400 X411	XXX06 XXX05 XXX09 Xxx	X312 X301 X314 X317 X410	XXX071	xxxxxxxx: XXX = 1&xxxx;100 mg/kg XX xxxxxx: XXX = 175 xx/xx XX Xxxx Sens. 1 X; X317: X ≥ 0,0015 % X = 1“
„616-228-00-4	3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’-xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxx; xxxxxxxxxxxx	–	907204-31-3	Xxxx. Xxxxxxx Xxxxx 1 Aquatic Chronic 1	X362 X400 X410	XXX09 Xxx	X362 X410		X = 1 X = 1“
„616-230-00-5	N-(hydroxymethyl)akrylamid; xxxxxxxxxxxxxxxxx; [XXX]	213-103-2	924-42-5	Xxxx. 1B Muta. 1X XXXX XX 1	X350 X340 X372 (periferní xxxxxxx xxxxxx)	XXX08 Xxx	X350 X340 X372 (periferní xxxxxxx xxxxxx)“
„616-231-00-0	5-xxxxx-1,3-xxxxxxxx-X-[2-(4-xxxxxxxxxxxx-2-xx)xxxxx]-1X-xxxxxxx-4-xxxxxxxxxx; 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxx; xxxxxxxxx	–	494793-67-8	Xxxx. 2 Xxxxxxx Xxxxx 1 Aquatic Xxxxxxx 1	X351 X400 X410	XXX08 XXX09 Xxx	X351 X410		X = 1 X = 1“
„616-232-00-6	iprovalikarb (XXX); xxxxxxxxx [(2X)-3-xxxxxx-1-{[1-(4-xxxxxxxxxxx)xxxxx]xxxxx}-1-xxxxxxxx-2-xx]xxxxxxxx	–	140923-17-7	Xxxx. 2	H351	GHS08 Wng	H351“
„616-233-00-1	silthiofam (XXX); X-xxxxx-4,5-xxxxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxx	–	175217-20-6	XXXX RE 2 Xxxxxxx Xxxxxxx 2	X373 X411	XXX08 XXX09 Xxx	X373 X411“
„650-057-00-6	Xxxxxxx, xxxxxxx [xxxx lisovaný za xxxxxxx xx semen xxxxxxxx Azadirachta xxxxxx xxx xxxxxxxx, xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxx xxxxxxxxx]	283-644-7	84696-25-3	Xxxxxxx Xxxxxxx 3	X412		X412“

xxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxx 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616–014–00–0 a 617–006–00-X se xxxxxxxxx xxxxxx položkami:

Indexové xxxxx	Xxxxxxxx xxxxx	Xxxxx XX	Xxxxx XXX	Xxxxxxxxxxx		Xxxxxxxx			Xxxxxxxxxx xxxxxxx. xxxxxx, multiplikační xxxxxxx x XXX	Xxxxxxxx
Indexové xxxxx	Xxxxxxxx xxxxx	Xxxxx XX	Xxxxx XXX	Xxxx xxxx x kategorií xxxxxxxxxxxxx	Xxxx xxxxxxxxxxxx vět x xxxxxxxxxxxxx	Xxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxxx xxxx	Xxxx xxxxxxxxxxxx vět x nebezpečnosti	Kódy xxxxx. xxxxxxxxxxxx xxx x xxxxxxxxxxxxx	Xxxxxxxxxx xxxxxxx. xxxxxx, multiplikační xxxxxxx x XXX	Xxxxxxxx
„007-004-00-1	xxxxxxxx xxxxxxx …% [X &xx; 70 %]	231-714-2	7697-37-2	Xx. Xxx. 2 Acute Xxx. 1 Xxxx Corr. 1 X	X272 X330 X314	XXX03 XXX06 XXX05 Xxx	X272 X330 X314	XXX071	Xx. Xxx. 2; X272: C ≥ 99 % Xx. Xxx. 3; X272: 70 % ≤ X < 99 %	X“
„014-018-00-1	xxxxxxxxxxxxxxxxxxxxxxxxxxx; [X4]	209-136-7	556-67-2	Xxxx. 2 Xxxxxxx Chronic 1	X361x *** X410	XXX08 XXX09 Xxx	X361x *** X410		X = 10“
„015-134-00-5	pirimifos-methyl (XXX); X-[2-(xxxxxxxxxxx)-6-xxxxxxxxxxxxxxx-4-xx]-X,X-xxxxxxxx-xxxxxxxxxxxxx	249-528-5	29232-93-7	Xxxxx Xxx. 4 STOT XX 1 Xxxxxxx Acute 1 Xxxxxxx Xxxxxxx 1	X302 X372 (xxxxxxx xxxxxx) X400 X410	XXX07 XXX08 XXX09 Xxx	X302 X372 (nervový xxxxxx) X410		xxxxxx: XXX = 1 414 xx/xx TH M = 1&xxxx;000 X = 1&xxxx;000 “
„015-181-00-1	xxxxxx	232-260-8	7803-51-2	Xxxx. Gas 1 Press. Xxx Xxxxx Xxx. 1 Xxxx Xxxx. 1X Xxxxxxx Xxxxx 1	X220 X330 X314 X400	XXX02 XXX04 XXX06 XXX05 XXX09 Xxx	X220 X330 X314 X400		xxxxxxxxx: XXX = 10 xxxX (xxxxx)	X“
„050-021-00-4	xxxxxxxxxxxxxxxxxxxxx	222-583-2	3542-36-7	Xxxx. 1X Xxxxx Xxx. 2 XXXX RE 1 Xxxxxxx Xxxxxxx 3	X360X X330 X372 ** X412	XXX08 XXX06 Xxx	X360X X330 X372 ** X412		Xxxx. 1X; X360 X: X ≥ 0,03 % inhalační: XXX = 0.098 xx/X (prach xxxx xxxx)“
„050-027-00-7	2-xxxxxxxxxx 10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxxxxxxxxxx; [XXXX]	239-622-4	15571-58-1	Xxxx. 1X XXXX XX 1 Aquatic Xxxxx 1 Aquatic Chronic 1	X360X X372 (xxxxxxxx xxxxxx) X400 X410	XXX08 XXX09 Xxx	X360X X372 (xxxxxxxx xxxxxx) X410“
„082-013-00-1	xxxxxxx prášek; [xxxxxx částic &xx; 1 mm]	231-100-4	7439-92-1	Repr. 1 X Xxxx. Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1	H360FD H362 H400 H410	GHS08 GHS09 Dgr	H360FD H362 H410		Repr. 1 X; X360X: X ≥ 0,03 % X = 1 X = 10“
„603-014-00-0	2-xxxxxxxxxxx-1-xx; xxxxxxxxxxxxxxxxxxxxxxxxxxxx	203-905-0	111-76-2	Xxxxx Tox. 4* Xxxxx Xxx. 4 Xxxx Xxxxx. 2 Xxx Irrit. 2	X332 X302 X315 X319	XXX07 Xxx	X332 X302 X315 X319		xxxxxx: ATE = 1&xxxx;200 mg/kg XX“
„603-065-00-9	x-xxx(2,3-xxxxxxxxxxxx)xxxxxx; xxxxxxxxxxxxxxxxxxxxxxxxx	202-987-5	101-90-6	Xxxx. 1X Xxxx. 2 Xxxxx Xxx. 3 Xxxxx Xxx. 4 Xxxx Xxxxx. 2 Xxx Xxxxx. 2 Xxxx Xxxx. 1 Xxxxxxx Xxxxxxx 3	H350 H341 H311 H302 H315 H319 H317 H412	GHS08 GHS06 Dgr	H350 H341 H311 H302 H315 H319 H317 H412		dermální: ATE = 300 mg/kg XX xxxxxx: XXX = 500 xx/xx XX“
„607-177-00-9	xxxxxxxxxx-xxxxxx (XXX); xxxxxx-2-[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)-X-xxxxxxxxxxxxxxxxxxxxxxxx]xxxxxxx	401-190-1	101200-48-0	XXXX XX 2 Xxxx Xxxx. 1 Xxxxxxx Xxxxx 1 Aquatic Chronic 1	X373 X317 X400 X410	XXX08 XXX07 XXX09 Xxx	X373 X317 X410		X = 100 X = 100“
„607-256-00-8	xxxxxxxxxxxx (XXX); xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxx	–	131860-33-8	Xxxxx Xxx. 3 Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1	X331 X400 X410	XXX06 XXX09 Xxx	X331 X410		xxxxxxxxx: XXX = 0,7 xx/x (xxxxx xxxx xxxx) X = 10 X = 10“
„607-314-00-2	xxxxxxxxxxx (ISO); (RS)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl xxxxxxxxxxxxxx	247-525-3	26225-79-6	Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1	X400 X410	XXX09 Xxx	X410		X = 1 X = 1“
„609-041-00-4	2,4-dinitrofenol	200-087-7	51-28-5	Acute Xxx. 3 * Xxxxx Xxx. 3 Xxxxx Xxx. 2 XXXX RE 1 Aquatic Xxxxx 1	X331 X311 X300 X372 X400	XXX06 XXX08 XXX09 Xxx	X331 X311 X300 X372 X400		xxxxxxxx: XXX = 300 mg/kg XX xxxxxx: ATE = 30 xx/xx XX“
„609-064-00-X	xxxxxxxxx (XXX); 2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxx	–	104206-82-8	Xxxx. 2 XXXX XX 2 Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1	X361x X373 (xxx, xxxxxxx systém) H400 H410	GHS08 GHS09 Wng	H361d H373 (xxx, xxxxxxx xxxxxx) X410		X = 10 X = 10“
„613-112-00-5	xxxxxxxxxx (XXX); 2-xxxxx-2X-xxxxxxxxxx-3-xx; [XXX]	247-761-7	26530-20-1	Xxxxx Xxx. 2 Acute Tox. 3 Xxxxx Xxx. 3 Xxxx Xxxx. 1 Xxx Xxx. 1 Xxxx Sens. 1 X Xxxxxxx Acute 1 Xxxxxxx Chronic 1	H330 H311 H301 H314 H318 H317 H400 H410	GHS06 GHS05 GHS09 Dgr	H330 H311 H301 H314 H317 H410	EUH071	inhalační: XXX = 0,27 xx/x (xxxxx xxxx xxxx) xxxxxxxx: XXX = 311 xx/xx XX xxxxxx: ATE = 125 xx/xx XX Xxxx Xxxx. 1 X; X317: C ≥ 0,0015 % M = 100 X = 100“
„613-115-00-1	hymexazol (XXX); 3-xxxxxxx-5-xxxxxxxxxxxxxx	233-000-6	10004-44-1	Xxxx. 2 Xxxxx Xxx. 4 Xxx Xxx. 1 Xxxx Xxxx. 1 Xxxxxxx Chronic 2	X361x X302 X318 X317 X411	XXX08 XXX07 XXX05 XXX09 Xxx	X361x X302 X318 X317 X411		xxxxxx: XXX = 1&xxxx;600 xx/xx TH“
„613-125-00-6	hexythiazox (XXX); xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxx	–	78587-05-0	Xxxxxxx Acute 1 Xxxxxxx Xxxxxxx 1	H400 H410	GHS09 Wng	H410		M = 1 X = 1“
„613-202-00-4	xxxxxxxxxx (XXX); (X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxxxxxxxx)-1,2,4-xxxxxxx-3(2X)-xx	–	123312-89-0	Xxxx. 2 Repr. 2 Xxxxxxx Xxxxxxx 1	X351 X361xx X410	XXX08 XXX09 Xxx	X351 X361xx X410		X = 1“
„613-259-00-5	xxxxxxxxxxx (XXX); xxxxxxx xxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxx; [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxxxx-xxxxxxxxxxxxx	428-790-6	72963-72-5	Xxxx. 2 Xxxxx Xxx. 4 Xxxxx Tox. 4 XXXX SE 2 Xxxxxxx Xxxxx 1 Xxxxxxx Chronic 1	X351 X332 X302 X371 (nervový xxxxxx; xxxxxx, xxxxxxxxx) X400 X410	XXX08 XXX07 XXX09 Xxx	X351 X332 X302 X371 (xxxxxxx xxxxxx; xxxxxx, xxxxxxxxx) X410		xxxxxxxxx: XXX = 1,4 xx/x (prach xxxx xxxx) xxxxxx: XXX = 550 xx/xx XX X = 10 X = 10“
„616-014-00-0	xxxxx-xx-xxxx; ethylmethylketoxim, xxxxx(xxxxxx)xxxxxxxxx	202-496-6	96-29-7	Xxxx. 1X Xxxxx Xxx. 4 Acute Xxx. 3 XXXX SE 3 XXXX XX 1 STOT XX 2 Xxxx Xxxxx. 2 Xxx Xxx. 1 Xxxx Xxxx. 1	H350 H312 H301 H336 H370 (xxxxx xxxxxxx xxxxx) X373 (krevní xxxx) X315 X318 X317	XXX08 XXX06 XXX05 Xxx	X350 X312 X301 X336 X370 (horní dýchací xxxxx) X373 (krevní xxxx) X315 X318 X317		xxxxxxxx: XXX = 1&xxxx;100 xx/xx XX orální: XXX = 100 xx/xx XX“
„617-006-00-X	xxx(α,α-xxxxxxxxxxxxxx)xxxxxxx	201-279-3	80-43-3	Xxx. Perox. X Xxxx. 1X Xxxx Irrit. 2 Xxx Xxxxx. 2 Xxxxxxx Xxxxxxx 2	X242 X360X X315 X319 X411	XXX02 XXX08 XXX07 XXX09 Xxx	X242 X360X X315 X319 X411“

3)	xxxxxxx xxxxxxxxxxxx xxxxxxxxx číslům 601-064-00-8 x 607-693-00-4 xx xxxxxxx.

Plné znění - 32020R1182

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

XXXXXXXX XXXXXX X XXXXXXXXX PRAVOMOCI (EU) 2020/1182

xx dne 19. xxxxxx 2020,

kterým se xxx účely xxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxxx xxxxxxx xxxx část 3 xxxxxxx VI xxxxxxxx Xxxxxxxxxx parlamentu x Rady (XX) x. 1272/2008 o xxxxxxxxxxx, xxxxxxxxxx x xxxxxx látek x xxxxx

Článek 1

Xxxxxx 2

Xxxxx v xxxxxxxx x xxxxxxxxxxxx

PŘÍLOHA

Plné znění - 32020R1182

Na co čekáte? Nečekejte už ani minutu. Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

XXXXXXXX XXXXXX X XXXXXXXXX PRAVOMOCI (EU) 2020/1182

xx dne 19. xxxxxx 2020,

kterým se xxx účely xxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxxx xxxxxxx xxxx část 3 xxxxxxx VI xxxxxxxx Xxxxxxxxxx parlamentu x Rady (XX) x. 1272/2008 o xxxxxxxxxxx, xxxxxxxxxx x xxxxxx látek x xxxxx

Článek 1

Xxxxxx 2

Xxxxx v xxxxxxxx x xxxxxxxxxxxx

PŘÍLOHA

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.